Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Amgen revenue increased from $23.4 billion in 2019 to $25.4 billion in 2020, a (8.8%) increase.
Annual Revenue ($)
Amgen revenue was $25.42 b in FY, 2020 which is a (8.8%) year over year increase from the previous period.
Quarterly Revenue ($)
Annual Growth Rate (%)
Revenue Breakdown
Business Segment
Geographic Segment
Amgen revenue breakdown by business segment: 8.6% from Otezla, 25.9% from Other Products, 6.2% from Aranesp, 7.5% from XGEVA, 10.9% from Prolia, 9.0% from Neulasta, 19.7% from Enbrel and 12.3% from Other
Amgen revenue breakdown by geographic segment: 27.2% from Rest of World and 72.8% from United States
| FY, 2020 | FY, 2019 | FY, 2018 | |
|---|---|---|---|
| Other Revenues | $1.18 b | $1.16 b | $1.21 b |
| Other Products | $6.57 b | $4.96 b | $4.31 b |
| Sensipar/Mimpara | $551 m | $1.77 b | |
| EPOGEN | $867 m | $1.01 b | |
| Aranesp | $1.57 b | $1.73 b | $1.88 b |
| XGEVA | $1.9 b | $1.94 b | $1.79 b |
| Prolia | $2.76 b | $2.67 b | $2.29 b |
| Neulasta | $2.29 b | $3.22 b | $4.48 b |
| Enbrel | $5 b | $5.23 b | $5.01 b |
| KYPROLIS | $1.07 b | $1.04 b | |
| Otezla | $2.2 b | ||
| Repatha | $887 m |
| FY, 2020 | FY, 2019 | FY, 2018 | |
|---|---|---|---|
| Rest of World | $6.93 b | $6.14 b | $5.39 b |
| United States | $18.5 b | $17.22 b | $18.36 b |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.